nach oben

Erschienen in:

05.03.2018 | Harnblasenkarzinom | CME Fortbildung

Diagnostik und Therapie des Harnblasenkarzinoms

Schmerzlose Hämaturie immer ernst nehmen!

verfasst von: Dr. Jan-Friedrich Jokisch, Univ.-Prof. Dr. Ute Ganswindt, Prof. Dr. Marcus Hentrich, Dr. Tobias Grimm, Prof. Dr. Christian Stief, Prof. Dr. Alexander Karl

Erschienen in: CME | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Urothelkarzinom der Harnblase zählt zu den häufigsten Malignomen des unteren Harntrakts und nimmt bis zu 7% aller Krebserkrankungen in der westlichen Welt ein. Es kann durch mehrere exogene Noxen begünstigt oder ausgelöst werden. Als Hauptrisikofaktor gilt Tabakkonsum. Das Kardinalsymptom ist die schmerzlose Hämaturie. In der Diagnostik nimmt die Urethrozystoskopie neben der Sonografie den wichtigsten Stellenwert ein. Bei Tumornachweis sollte eine nachfolgende transurethrale Resektion der Blase (TUR-B) durchgeführt werden. Bei nicht-muskelinvasiven Tumoren kann eine Nachresektion und/oder eine adjuvante Instillationstherapie der Blase nötig sein. Bei muskelinvasiven Tumoren stellt die radikale Zystektomie nach einer neoadjuvanten systemischen Chemotherapie die kurative Therapie der Wahl dar. Im metastasierten Krankheitsstadium nimmt die palliative Chemotherapie den größten Stellenwert ein.

Onkologie L. S3-Leitlinie Früherkennung, Nachsorge des Harnblasenkarzinoms. 2016;1—371.

Chen C-H, Shun C-T, Huang K-H, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int [Internet] 2007 [cited 2018 Jan 15];100(2):281—6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17419696

Babjuk M, Böhle A, Burger M, et al. Guidelines on Bladder Cancer. 2014.

Negri E, La Vecchia C. Epidemiology and prevention of bladder cancer. Eur J Cancer Prev 2001;10:7–14.CrossRef

M. Babjuk (Chair), A. Böhle, M. Burger, E. Compérat, E. Kaasinen, J. Palou, M. Rouprêt, B.W.G. van Rhijn, S. Shariat, R. Sylvester RZ. EAU-Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). Eur Urol 2015;41:105–12.

Lamm DL. Carcinoma in situ. Urol Clin North Am [Internet] 1992 [cited 2016 May 19];19(3):499—508. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1636234

Witjes J a, Compérat E, Cowan NC, et al. Muscle-invasive and Metastatic Bladder Cancer. 2015

Satasivam P, Reeves F, Lin M, et al. The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary Australian patient cohort. BJU Int [Internet] 2012;110:80—4. Available from: http://dx.doi.org/10.1111/j.1464-410X.2012.11622.x

Tritschler S, Strittmatter F, Karl a, Stief C. [Urine marker systems for diagnosis of urothelial cancer]. Urologe A [Internet] 2013 [cited 2015 Feb 10];52(7):965—9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23784678

10.

Herlemann A, Wenter V, Kretschmer A, et al. (68)Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol [Internet] 2016 [cited 2016 Apr 15];Available from: http://www.sciencedirect.com/science/article/pii/S0302283816000099

11.

Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol [Internet] 2010 [cited 2016 Apr 20];57(4):595—606. Available from: http://www.sciencedirect.com/science/article/pii/S0302283809012032CrossRef

12.

Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol [Internet] 2014 [cited 2016 May 19];191(2):341—5. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4157345&tool=pmcentrez&rendertype=abstractCrossRef

13.

Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk. Eur Urol 2010;57(5):766–73.CrossRef

14.

Oddens J., Brausi M SR et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1, papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462–72.CrossRef

15.

Jokisch J-F, Karl A, Stief C. Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian J Urol [Internet] 2015;31(4):304—11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26604441CrossRef

16.

Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol [Internet] 2006 [cited 2016 May 19];7(1):43—51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16389183

17.

SÁNCHEZ-ORTIZ RF, HUANG WC, MICK R, VAN ARSDALEN KN, WEIN AJ, MALKOWICZ SB. An Interval Longer than 12 Weeks Between the Diagnosis of Muscle Invasion and Cystectomy is Associated with Worse Outcome in Bladder Carcinoma. J Urol [Internet] 2003;169(1):110—5. Available from: http://www.sciencedirect.com/science/article/pii/S0022534705640475CrossRef

18.

Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet [Internet] 1999 [cited 2016 Apr 20];354(9178):533—40. Available from: http://www.thelancet.com/article/S0140673699022928/fulltext

19.

Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol [Internet] 2005 [cited 2016 Mar 10];48(2):202—5; discussion 205—6. Available from: http://www.sciencedirect.com/science/article/pii/S0302283805002137CrossRef

20.

Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol [Internet] 2012 [cited 2016 Apr 20];61(5):1070—1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22336379CrossRef

21.

Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol 2011;59:1009–18.CrossRef

22.

Bellmunt J, Orsola a., Leow JJ, Wiegel T, De Santis M, Horwich a. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(August):iii40–8.CrossRef

23.

Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol [Internet] 2014 [cited 2016 Mar 10];66(1):42—54. Available from: http://www.sciencedirect.com/science/article/pii/S0302283813008610CrossRef

24.

Von Der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8.CrossRef

25.

Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013;24:1466–72.CrossRef

26.

Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature. J Urol [Internet] 2016 [cited 2017 Nov 26];195(2):254—63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26410730CrossRef

27.

Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol [Internet] 2016 [cited 2017 Nov 26];27(1):49—61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26487582CrossRef

28.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol [Internet] 2017 [cited 2017 Nov 2];18(3):312—22. Available from: http://www.sciencedirect.com/science/article/pii/S1470204517300657

29.

Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet [Internet] 2016 [cited 2017 Nov 7];387(10031):1909—20. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673616005614

30.

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med [Internet] 2017;376:1015—26. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1613683

31.

Rodel C, Grabenbauer GG, Kuhn R, Papa- dopoulos T, Dunst J, Meyer M et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin on- Col Off J Am Soc Clin Oncol 2002;14:3061–71.CrossRef

32.

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP et al. Long-term outcomes in patients with muscle-invasive blad- der cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol Off J Ameri- can Soc Clin Oncol 2014;32(34):3801–9.CrossRef

33.

No Witjes AJ, Lebret T, Compéreat EM et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol [Internet] 2016;Available from: http://dx.doi.org/10.1016/j.eururo.2016.06.020Title

Titel: Diagnostik und Therapie des Harnblasenkarzinoms
Schmerzlose Hämaturie immer ernst nehmen!
verfasst von: Dr. Jan-Friedrich Jokisch
Univ.-Prof. Dr. Ute Ganswindt
Prof. Dr. Marcus Hentrich
Dr. Tobias Grimm
Prof. Dr. Christian Stief
Prof. Dr. Alexander Karl
Publikationsdatum: 05.03.2018
Verlag: Springer Medizin
Schlagwörter: Harnblasenkarzinom
Harnblasenkarzinom
Zytostatische Therapie
Urothelkarzinom
Instillationstherapie
Zystektomie
Hämaturie
Urothelkarzinom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
Erschienen in: CME / Ausgabe 3/2018
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI: https://doi.org/10.1007/s11298-018-6418-6

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Evidenzbasiertes Rezept gegen Reizdarm

So entlasten Sie das Herz

Antikörpernachweis aus Nasensekret

Hypoparathyreoidismus kausal behandeln

Heilen mittels Wirkstoff-Recycling

Ibuprofen: Grund für Fertilitätsprobleme?